Buy 3-Hydroxymorphinan (3-HM) Cas 39131-41-4

Buy 3-Hydroxymorphinan (3-HM) Cas 39131-41-4

3-Hydroxymorphinan (3-HM), or morphinan-3-ol, is a psychoactive drug of the morphinan family.^[1] It is the racemic counterpart to norlevorphanol.

The dextrorotatory stereoisomer of the compound is an active metabolite of dextromethorphan, dextrorphan, and 3-methoxymorphinan,^[2] and similarly to them has potent neuroprotective and neurotrophic effects on LTS– and MPTP-treated dopaminergic neurons of the nigrostriatal pathway,^[3][4] but notably without producing any neuropsychotoxic side effects (e.g., dissociation or hallucinations) or having any anticonvulsant actions.^[5][6] It does not seem to bind to the NMDA receptor,^[6] and instead, its neuroprotective properties appear result from inhibition of glutamate release via the suppression of presynaptic voltage-dependent Ca²⁺ entry and protein kinase C activity.^[7] In any case, as such, the compound has been investigated as a potential management of Parkinson’s disease medication (antiparkinsonian agent). A prodrug, GCC1290K, has been developed on account of 3-HM’s poor bioavailability (18%), and a New Drug Application has been approved for it by the United States Food and Drug Administration.^[6] It is currently undergoing clinical trials for the treatment of Parkinson’s disease.^[6] It does not have a Controlled Substances Act 1970 schedule, ACSCN, or annual aggregate manufacturing quota and may not necessarily be controlled, whilst norlevorphanol is; none of the dextrorotary derivatives of the dromoran and norlevorphanol sub-families of morphinan derivatives are controlled as they do not have opioid activity but the other racemic compounds are.^[8]

3-HM’s levorotatory stereoisomer, norlevorphanol, in contrast to (+)-3-HM, is an opioid analgesic.^[9] It was never marketed as such however, probably due to a combination of the facts that norlevorphanol has low bioavailability and that its potency is diminished compared to its N–methylated analogue levorphanol.^[10]